Induction Optimization with Stelara for Crohn s Disease

Brief description of study

The purpose of this study is to compare the effectiveness of a second weight based dose of Stelara given intravenously to the standard dose administered subcutaneously at 8 weeks. In this study, the second weight-based intravenous induction dose of Stelara is considered investigational because it is outside of the FDA-approved dosing or “off-label”.

Clinical Study Identifier: s19-01401 Identifier: NCT04629196
Principal Investigator: David P Hudesman.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.